GGrantIndex
← Leaderboards

Susheela Tridandapani

Ohio State University

$6,556,394
Attributed
$8,839,505
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $667.3K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,839,505 · 6

By mechanism

R01$5,996,941 · 4
P01$2,842,564 · 2

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Mediating

Research focus

MediatingMacrophageResponseMolecularAntibodiesPhagocytosisMonocyteInflammatoryBaseMalignant NeoplasmsEventCellsReceptorNeoplastic CellAntibody TherapyTumorPlayEffector CellCytokineSignal TransductionImmunotherapyIn VivoSignal PathwayCancer Therapy

Grant awards (27)

Novel enhancement of antibody therapy through NOD2 activation$614,578
R01 · FY2025 · CA · contact PI
Novel enhancement of antibody therapy through NOD2 activation$621,637
R01 · FY2024 · CA · contact PI
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$352,513
R01 · FY2021 · CA · contact PI
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$351,988
R01 · FY2020 · CA · contact PI
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$340,933
R01 · FY2019 · CA · contact PI
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$350,436
R01 · FY2018 · CA · contact PI
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$347,783
R01 · FY2017 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$319,550
R01 · FY2017 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FCy RECEPTOR FUNCTION$333,663
P01 · FY2016 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$319,550
R01 · FY2016 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FCy RECEPTOR FUNCTION$333,663
P01 · FY2015 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$319,550
R01 · FY2015 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FCy RECEPTOR FUNCTION$323,654
P01 · FY2014 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$309,712
R01 · FY2014 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$317,993
R01 · FY2013 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FCy RECEPTOR FUNCTION$314,006
P01 · FY2013 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FCy RECEPTOR FUNCTION$335,152
P01 · FY2012 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FC-GAMMA RECEPTOR FUNCTION$243,783
P01 · FY2011 · CA · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FC-GAMMA RECEPTOR FUNCTION$251,346
P01 · FY2010 · CA · contact PI
SHIP-2 influence on macrophage Fc receptor function$278,119
R01 · FY2009 · AI · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FC-GAMMA RECEPTOR FUNCTION$246,436
P01 · FY2009 · CA · contact PI
SHIP-2 influence on macrophage Fc receptor function$278,119
R01 · FY2008 · AI · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FC-GAMMA RECEPTOR FUNCTION$238,366
P01 · FY2008 · CA · contact PI
SHIP-2 influence on macrophage Fc receptor function$283,506
R01 · FY2007 · AI · contact PI
HOMEOSTATIC CONTROL OF MACROPHAGE FC-GAMMA RECEPTOR FUNCTION$222,495
P01 · FY2007 · CA · contact PI
SHIP-2 influence on macrophage Fc receptor function$291,974
R01 · FY2006 · AI · contact PI
SHIP-2 influence on macrophage Fc receptor function$299,000
R01 · FY2005 · AI